Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001248PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION
WO 26.01.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2022/107134 Applicant JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Inventor MO, Xiyele
The disclosure relates to a pharmaceutical composition containing an anti-TROP2 antibody drug conjugate and its application. Specifically, the disclosure relates to a pharmaceutical composition comprising an antibody drug conjugate in a buffer. The pharmaceutical composition has good stability.
2.WO/2023/001257ANTI-SUPPRESSION OF TUMORIGENICITY 2 ANTIBODY AND LIQUID COMPOSITION CONTAINING SAME
WO 26.01.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/107198 Applicant MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. Inventor ZHANG, Yanzhen
An anti-suppression of tumorigenicity 2 (ST2) antibody or a fragment thereof. The anti-ST2 antibody or the fragment thereof can block the binding of IL-33 to a ST2 protein, and inhibit a downstream signaling pathway thereof, thereby exerting a therapeutic effect in diseases associated with IL-33/ST2 signaling pathway activation. In addition, a stable liquid antibody preparation containing the anti-ST2 antibody or the fragment thereof is further provided.
3.WO/2023/004287COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER
WO 26.01.2023
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
Appl.No PCT/US2022/073845 Applicant REGENERON PHARMACEUTICALS, INC. Inventor DADI-MEHMETAJ, Saida
This disclosure relates to novel triple combination therapies of an oncolytic virus, a PD-1 pathway inhibitor, and a CTLA4 inhibitor for treating or inhibiting the growth of a tumor in a patient with cancer.
4.WO/2023/001303PHARMACEUTICAL COMPOSITION AND USE
WO 26.01.2023
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/CN2022/107522 Applicant AKESO BIOPHARMA, INC Inventor WANG, Zhongmin
A pharmaceutical composition comprising an anti-TIGIT antibody or an antigen-binding fragment thereof, and an anti-CTLA4-anti-PD-1 bispecific antibody or an antigen-binding fragment thereof. Specifically, a heavy chain variable region of the antibody contains HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 3-5, respectively, and a light chain variable region contains LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 8-10, respectively.
5.WO/2023/001258PHARMACEUTICAL USE OF ANTI-TUMOR INHIBIN 2 ANTIBODY
WO 26.01.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/107205 Applicant MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. Inventor ZHENG, Bin
Provided is the use of a new anti-tumor inhibin 2 (ST2) antibody in the preparation of a drug for preventing or treating inflammatory, allergic or autoimmune diseases. The anti-ST2 antibody can bind to human ST2 with a high affinity, and can block the binding of human ST2 and human IL-33, thereby being capable of effectively inhibiting IL-33/ST2 signaling pathways. The anti-ST2 antibody has the effects of positively preventing and treating inflammatory, allergic or autoimmune diseases.
6.WO/2023/004348ENGINEERED COMPOSITIONS FOR BONE-TARGETED THERAPY
WO 26.01.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/073940 Applicant WILLIAM MARSH RICE UNIVERSITY Inventor XIAO, Han
The present disclosure provides methods for treating bone disease, such as bone cancers or bone metastasis of cancers, by administering an engineered bone-targeting compositions, such as an antibody or one or more polypeptides, such as an antibody or polypeptide engineered to comprise bone-homing peptide(s). Further provided herein are bone-targeting compositions, such as an antibody or one or more polypeptides, such as an antibody or polypeptide engineered to comprise bone-homing peptide(s).
7.WO/2023/001228PHARMACEUTICAL COMPOSITION OF ANTI-ANGPTL3 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND ITS APPLICATION
WO 26.01.2023
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
Appl.No PCT/CN2022/106993 Applicant JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Inventor YANG, Xiqin
A pharmaceutical composition of an anti-ANGPTL3 antibody or an antigen binding fragment thereof and its application. Specifically, the pharmaceutical composition comprises an anti-ANGPTL3 antibody or an antigen binding fragment thereof and an acetic acid sodium acetate buffer. The pharmaceutical composition may also comprise a sugar and a surfactant. The pharmaceutical composition has good antibody stability.
8.WO/2023/001304DRUG FOR PREVENTING, ALLEVIATING OR TREATING MUCOSAL ADHESION AND USE THEREOF
WO 26.01.2023
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/CN2022/107526 Applicant SHANGHAI SYNVIDA BIOTECHNOLOGY CO. LTD. Inventor LIU, Junling
Provided is a drug for preventing, alleviating or treating adhesion and a use thereof. A fibroblast which has been subjected to external stimulation in a body cavity contains an activated negative regulatory receptor PEAR1. The deletion of the fibroblast PEAR1 can significantly promote in vivo mucosal adhesion formation. A PEAR1 agonist can specifically inhibit fibroblast activation, synthesize an extracellular matrix, and ameliorate the adhesion lesion. By administering the PEAR1 agonist, the formation of adhesion can be effectively prevented. Also provided is a PEAR1 agonistic antibody that does not affect the repair and healing of normal tissue and does not cause the tissue to be in an anoxic state. Moreover, the antibody drug has a long half-life, is easily diffused, has few side effects, and has a convenient route of administration.
9.WO/2023/001154B7-H3 ANTIBODY AND USE THEREOF
WO 26.01.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/106546 Applicant EXCELMAB INC. Inventor ZHANG, Wenjun
The present application provides a B7-H3 antibody and a use thereof The heavy chain complementarity determining regions of the B7-H3 antibody comprise the amino acid sequences shown in SEQ ID NOs. 6-8, and the light chain complementarity determining regions of the B7-H3 antibody comprise the amino acid sequences shown in SEQ ID NOs. 14-16. The B7-H3 antibody can bind, with high affinity, to a B7-H3 antigen and cells expressing the B7-H3 antigen, and can efficiently mediate PBMC to kill B7-H3 positive tumors. A B7-H3×CD3 bispecific antibody is constructed by using the B7-H3 antibody. The bispecific antibody exhibits high affinity and stability, and can effectively mediate PBMC to kill tumor cells.
10.WO/2023/004289PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE
WO 26.01.2023
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2022/073850 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor YEE, Cassian
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigens FANCI, RAD51, and PBK. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.